| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Frovatriptan | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Frovatriptan | hsa00190 | Oxidative phosphorylation | 1.10E-03 | 3 | Q16718, P36542, O14521 | NDUFA5, ATP5C1, SDHD | More | | | Frovatriptan | hsa00310 | Lysine degradation | 4.57E-02 | 2 | Q96KQ7, Q02809 | EHMT2, PLOD1 | More | | | Frovatriptan | hsa00340 | Histidine metabolism | 4.52E-02 | 1 | O95954 | FTCD | More | | | Frovatriptan | hsa00350 | Tyrosine metabolism | 3.40E-02 | 1 | P28332 | ADH6 | More | | | Frovatriptan | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | | Frovatriptan | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Frovatriptan | hsa00562 | Inositol phosphate metabolism | 2.00E-02 | 4 | P27987, P19174, P42338, Q02252 | ITPKB, PLCG1, PIK3CB, ALDH6A1 | More | | | Frovatriptan | hsa00564 | Glycerophospholipid metabolism | 9.70E-03 | 2 | Q9Y259, P49619 | CHKB, DGKG | More | | | Frovatriptan | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | | Frovatriptan | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | | Frovatriptan | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Frovatriptan | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.67E-02 | 2 | P40925, P15104 | MDH1, GLUL | More | | | Frovatriptan | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Frovatriptan | hsa00790 | Folate biosynthesis | 2.45E-02 | 2 | Q92820, P07101 | GGH, TH | More | | | Frovatriptan | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.24E-03 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | | | Frovatriptan | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.40E-04 | 3 | P78417, P28332, P11712 | GSTO1, ADH6, CYP2C9 | More | | | Frovatriptan | hsa00982 | Drug metabolism - cytochrome P450 | 8.40E-04 | 3 | P11712, P78417, P28332 | CYP2C9, GSTO1, ADH6 | More | | | Frovatriptan | hsa01100 | Metabolic pathways | 2.25E-02 | 7 | Q9Y259, Q13956, P49619, O95954, Q02318, Q9UBX8, P35573 | CHKB, PDE6H, DGKG, FTCD, CYP27A1, B4GALT6, AGL | More | | | Frovatriptan | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Frovatriptan | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | | | Frovatriptan | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | | Frovatriptan | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | | | Frovatriptan | hsa03010 | Ribosome | 2.45E-02 | 2 | P46777, P50914 | RPL5, RPL14 | More | | | Frovatriptan | hsa03013 | RNA transport | 1.58E-05 | 15 | O14980, Q09161, O14893, P38919, P37198, Q7Z3B4, P35658, P47813, Q14152, P55884, O75822, Q14240, Q9BZI7, Q06787, P51114 | XPO1, NCBP1, GEMIN2, EIF4A3, NUP62, NUP54, NUP214, EIF1AX, EIF3A, EIF3B, EIF3J, EIF4A2, UPF3B, FMR1, FXR1 | More | | | Frovatriptan | hsa03020 | RNA polymerase | 3.00E-02 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | | | Frovatriptan | hsa03022 | Basal transcription factors | 2.97E-03 | 3 | P20226, O00268, Q15544 | TBP, TAF4, TAF11 | More | | | Frovatriptan | hsa03040 | Spliceosome | 1.28E-06 | 14 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | | Frovatriptan | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | | Frovatriptan | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | | Frovatriptan | hsa03320 | PPAR signaling pathway | 1.62E-02 | 2 | Q13133, Q02318 | NR1H3, CYP27A1 | More | | | Frovatriptan | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | | Frovatriptan | hsa04012 | ErbB signaling pathway | 2.00E-02 | 4 | P16333, P17252, P19174, P42338 | NCK1, PRKCA, PLCG1, PIK3CB | More | | | Frovatriptan | hsa04014 | Ras signaling pathway | 9.77E-05 | 12 | P42338, P20827, P49767, Q13009, P17252, P14921, Q7LDG7, P0DP23, P62873, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, PRKCA, ETS1, RASGRP2, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | | Frovatriptan | hsa04015 | Rap1 signaling pathway | 5.98E-04 | 10 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P0DP23, P17252, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, CALM1, PRKCA, PLCG1 | More | | | Frovatriptan | hsa04020 | Calcium signaling pathway | 4.34E-02 | 6 | P27987, P17252, O15399, P19174, P0DP23, P49767 | ITPKB, PRKCA, GRIN2D, PLCG1, CALM1, VEGFC | More | | | Frovatriptan | hsa04024 | cAMP signaling pathway | 4.34E-02 | 6 | P42338, P0DP23, Q13370, O15399, P25963, Q13009 | PIK3CB, CALM1, PDE3B, GRIN2D, NFKBIA, TIAM1 | More | | | Frovatriptan | hsa04062 | Chemokine signaling pathway | 4.05E-04 | 14 | P09769, P07948, P42338, P19174, P62873, P63218, P50151, P43250, Q7LDG7, Q13009, P14598, P42224, P25963, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, NCF1, STAT1, NFKBIA, PIK3R5 | More | | | Frovatriptan | hsa04064 | NF-kappa B signaling pathway | 2.35E-02 | 4 | P01584, P63279, Q8NHW4, Q9NQC7 | IL1B, UBE2I, CCL4L2, CYLD | More | | | Frovatriptan | hsa04070 | Phosphatidylinositol signaling system | 3.29E-03 | 6 | P19174, P0DP23, P42338, P23743, P27987, P17252 | PLCG1, CALM1, PIK3CB, DGKA, ITPKB, PRKCA | More | | | Frovatriptan | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | | Frovatriptan | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | | Frovatriptan | hsa04110 | Cell cycle | 3.57E-02 | 3 | Q9UBD5, P06493, P33981 | ORC3, CDK1, TTK | More | | | Frovatriptan | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Frovatriptan | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | | | Frovatriptan | hsa04144 | Endocytosis | 1.67E-02 | 8 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, GIT2, SNX12 | More | | | Frovatriptan | hsa04146 | Peroxisome | 4.83E-02 | 4 | O96011, P56589, Q9UKG9, O75521 | PEX11B, PEX3, CROT, ECI2 | More | | | Frovatriptan | hsa04151 | PI3K-Akt signaling pathway | 2.03E-03 | 16 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P62873, P63218, P50151, P16144, O15335, Q13751, P14784, P01568, P17252, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNB1, GNG5, GNG10, ITGB4, CHAD, LAMB3, IL2RB, IFNA21, PRKCA, CCND3 | More | | | Frovatriptan | hsa04213 | Longevity regulating pathway - multiple species | 2.82E-02 | 3 | Q08828, P51828, P0DMV8 | ADCY1, ADCY7, HSPA1A | More | | | Frovatriptan | hsa04217 | Necroptosis | 2.97E-03 | 11 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, P15104, Q6FI13, Q99878, O43633 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, GLUL, H2AC18; H2AC19, H2AC14, CHMP2A | More | | | Frovatriptan | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | | Frovatriptan | hsa04270 | Vascular smooth muscle contraction | 6.96E-03 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | | Frovatriptan | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | | Frovatriptan | hsa04360 | Axon guidance | 5.10E-04 | 8 | P16333, P20827, O95631, P17252, P42338, P07332, P23528, P19174 | NCK1, EFNA1, NTN1, PRKCA, PIK3CB, FES, CFL1, PLCG1 | More | | | Frovatriptan | hsa04370 | VEGF signaling pathway | 7.68E-03 | 3 | P19174, P42338, P17252 | PLCG1, PIK3CB, PRKCA | More | | | Frovatriptan | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | | Frovatriptan | hsa04390 | Hippo signaling pathway | 4.35E-02 | 2 | P63261, O15105 | ACTG1, SMAD7 | More | | | Frovatriptan | hsa04510 | Focal adhesion | 7.77E-03 | 9 | P16144, O75369, P42338, Q15942, P17252, O15335, Q13751, Q13489, P49767 | ITGB4, FLNB, PIK3CB, ZYX, PRKCA, CHAD, LAMB3, BIRC3, VEGFC | More | | | Frovatriptan | hsa04530 | Tight junction | 3.60E-03 | 5 | P63261, P16989, P56750, Q92974, Q14247 | ACTG1, CSDA, CLDN17, ARHGEF2, CTTN | More | | | Frovatriptan | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | | Frovatriptan | hsa04613 | Neutrophil extracellular trap formation | 2.18E-03 | 7 | P04908, Q93077, P62807, O60814, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | | Frovatriptan | hsa04623 | Cytosolic DNA-sensing pathway | 1.35E-03 | 4 | P01584, P01568, P25963, Q8NHW4 | IL1B, IFNA21, NFKBIA, CCL4L2 | More | | | Frovatriptan | hsa04640 | Hematopoietic cell lineage | 1.82E-02 | 5 | P11215, P20023, P07766, P01730, P09564 | ITGAM, CR2, CD3E, CD4, CD7 | More | | | Frovatriptan | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | | | Frovatriptan | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | | Frovatriptan | hsa04658 | Th1 and Th2 cell differentiation | 2.27E-02 | 4 | P07766, P19174, P01730, P06239 | CD3E, PLCG1, CD4, LCK | More | | | Frovatriptan | hsa04659 | Th17 cell differentiation | 3.20E-04 | 12 | P25963, P19174, P01730, P06239, P42224, P14784, P14778, P40189, P84022, Q13485, P08238, P07766 | NFKBIA, PLCG1, CD4, LCK, STAT1, IL2RB, IL1R1, IL6ST, SMAD3, SMAD4, HSP90AB1, CD3E | More | | | Frovatriptan | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | | Frovatriptan | hsa04664 | Fc epsilon RI signaling pathway | 1.25E-03 | 5 | P42338, P17252, P07948, P19174, P09917 | PIK3CB, PRKCA, LYN, PLCG1, ALOX5 | More | | | Frovatriptan | hsa04666 | Fc gamma R-mediated phagocytosis | 8.08E-03 | 5 | P42338, P19174, P23528, P14598, P17252 | PIK3CB, PLCG1, CFL1, NCF1, PRKCA | More | | | Frovatriptan | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | | Frovatriptan | hsa04670 | Leukocyte transendothelial migration | 4.66E-02 | 4 | P11215, P60709, P19174, P12814 | ITGAM, ACTB, PLCG1, ACTN1 | More | | | Frovatriptan | hsa04713 | Circadian entrainment | 1.24E-02 | 5 | O15399, P0DP23, P17252, P62873, P50151 | GRIN2D, CALM1, PRKCA, GNB1, GNG10 | More | | | Frovatriptan | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Frovatriptan | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Frovatriptan | hsa04724 | Glutamatergic synapse | 8.08E-03 | 5 | O15399, P17252, P62873, P50151, P15104 | GRIN2D, PRKCA, GNB1, GNG10, GLUL | More | | | Frovatriptan | hsa04725 | Cholinergic synapse | 4.26E-02 | 4 | P17252, P62873, P50151, P42338 | PRKCA, GNB1, GNG10, PIK3CB | More | | | Frovatriptan | hsa04726 | Serotonergic synapse | 2.54E-02 | 5 | P17252, P62873, P50151, P33260, P09917 | PRKCA, GNB1, GNG10, CYP2C18, ALOX5 | More | | | Frovatriptan | hsa04727 | GABAergic synapse | 1.23E-02 | 4 | P62873, P50151, P15104, P17252 | GNB1, GNG10, GLUL, PRKCA | More | | | Frovatriptan | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | | Frovatriptan | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | | Frovatriptan | hsa04744 | Phototransduction | 1.67E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | | Frovatriptan | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.01E-02 | 4 | P01584, Q08828, P51828, P0DP23 | IL1B, ADCY1, ADCY7, CALM1 | More | | | Frovatriptan | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | | Frovatriptan | hsa04914 | Progesterone-mediated oocyte maturation | 1.24E-02 | 5 | P42338, Q13370, Q9UJX4, P30304, P08238 | PIK3CB, PDE3B, ANAPC5, CDC25A, HSP90AB1 | More | | | Frovatriptan | hsa04915 | Estrogen signaling pathway | 3.17E-02 | 5 | Q08828, P51828, P0DMV8, P0DP23, Q15788 | ADCY1, ADCY7, HSPA1A, CALM1, NCOA1 | More | | | Frovatriptan | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | | Frovatriptan | hsa04926 | Relaxin signaling pathway | 1.10E-03 | 10 | P25963, P42338, P62873, P50151, P18848, P22694, P49767, P14780, P17252, P30679 | NFKBIA, PIK3CB, GNB1, GNG10, ATF4, PRKACB, VEGFC, MMP9, PRKCA, GNA15 | More | | | Frovatriptan | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | | Frovatriptan | hsa04932 | Non-alcoholic fatty liver disease | 7.01E-05 | 11 | P01375, P49841, O43521, P48023, O75460, P01584, P13073, P12074, Q16718, O95298, O14521 | TNF, GSK3B, BCL2L11, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFA5, NDUFC2, SDHD | More | | | Frovatriptan | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.76E-03 | 7 | P84022, Q13485, P42224, P42338, P49767, P17252, P19174 | SMAD3, SMAD4, STAT1, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | | Frovatriptan | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Frovatriptan | hsa04970 | Salivary secretion | 2.43E-03 | 6 | P07550, Q08828, P51828, P22694, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, CALM1, CAMP | More | | | Frovatriptan | hsa04976 | Bile secretion | 3.14E-03 | 5 | O43315, Q08828, P51828, P08183, Q14032 | AQP9, ADCY1, ADCY7, ABCB1, BAAT | More | | | Frovatriptan | hsa05014 | Amyotrophic lateral sclerosis | 2.72E-02 | 10 | P01375, Q16718, O14521, P36542, P09651, Q7Z3B4, P35658, P43243, Q09161, Q16629 | TNF, NDUFA5, SDHD, ATP5C1, HNRNPA1, NUP54, NUP214, MATR3, NCBP1, SFRS7 | More | | | Frovatriptan | hsa05016 | Huntington disease | 2.46E-02 | 9 | O95298, P13073, P12074, P24928, P30876, P62487, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, ERN1, PSMB4, PSMD12 | More | | | Frovatriptan | hsa05020 | Prion disease | 4.56E-03 | 6 | Q16718, O14521, Q92736, O60282, P49841, Q16539 | NDUFA5, SDHD, RYR2, KIF5C, GSK3B, MAPK14 | More | | | Frovatriptan | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | | Frovatriptan | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | | Frovatriptan | hsa05032 | Morphine addiction | 1.24E-02 | 5 | P62873, P50151, Q13370, P17252, P43250 | GNB1, GNG10, PDE3B, PRKCA, GRK6 | More | | | Frovatriptan | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Frovatriptan | hsa05110 | Vibrio cholerae infection | 3.15E-02 | 3 | Q13488, P17252, P19174 | TCIRG1, PRKCA, PLCG1 | More | | | Frovatriptan | hsa05132 | Salmonella infection | 4.83E-02 | 2 | O00471, O60282 | EXOC5, KIF5C | More | | | Frovatriptan | hsa05134 | Legionellosis | 2.82E-02 | 3 | P01584, Q9NR31, P0DMV8 | IL1B, SAR1A, HSPA1A | More | | | Frovatriptan | hsa05135 | Yersinia infection | 1.82E-02 | 4 | P60709, P06239, P19174, P01730 | ACTB, LCK, PLCG1, CD4 | More | | | Frovatriptan | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | | Frovatriptan | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | | Frovatriptan | hsa05145 | Toxoplasmosis | 3.45E-02 | 6 | P25963, Q13489, P42224, P09917, Q13751, P11142 | NFKBIA, BIRC3, STAT1, ALOX5, LAMB3, HSPA8 | More | | | Frovatriptan | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | | | Frovatriptan | hsa05150 | Staphylococcus aureus infection | 4.02E-03 | 6 | P21462, O75015, Q14532, P59665, P59666, P12838 | FPR1, FCGR3B, KRT32, DEFA1; DEFA1B, DEFA3, DEFA4 | More | | | Frovatriptan | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Frovatriptan | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | | Frovatriptan | hsa05163 | Human cytomegalovirus infection | 1.70E-03 | 14 | P42338, P25963, P62873, P50151, P0DP23, Q8NHW4, Q08828, P51828, P23458, P01584, P17252, Q13651, P30101, P01568 | PIK3CB, NFKBIA, GNB1, GNG10, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, IL1B, PRKCA, IL10RA, PDIA3, IFNA21 | More | | | Frovatriptan | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.56E-03 | 9 | P01568, P42224, P25963, P42338, P40189, P62873, P50151, P19174, P0DP23 | IFNA21, STAT1, NFKBIA, PIK3CB, IL6ST, GNB1, GNG10, PLCG1, CALM1 | More | | | Frovatriptan | hsa05168 | Herpes simplex virus 1 infection | 6.31E-03 | 13 | P25963, P01568, P42224, Q07955, Q01130, Q13243, Q13489, P30101, P42338, Q13398, Q03923, O75820, Q9UDV6 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, PDIA3, PIK3CB, ZNF211, ZNF85, ZNF189, ZNF212 | More | | | Frovatriptan | hsa05170 | Human immunodeficiency virus 1 infection | 7.66E-03 | 10 | P42338, P62873, P50151, P0DP23, P17252, P30101, P01568, P25963, P19174, P23528 | PIK3CB, GNB1, GNG10, CALM1, PRKCA, PDIA3, IFNA21, NFKBIA, PLCG1, CFL1 | More | | | Frovatriptan | hsa05171 | Coronavirus disease - COVID-19 | 3.30E-02 | 7 | P25963, P42224, P01568, P40189, P42338, P19174, P17252 | NFKBIA, STAT1, IFNA21, IL6ST, PIK3CB, PLCG1, PRKCA | More | | | Frovatriptan | hsa05200 | Pathways in cancer | 5.83E-06 | 29 | Q13751, P42338, P08238, P42224, P25963, P19174, P17252, P43246, P84022, Q13485, Q13547, P10826, P14923, P30281, Q13489, P49767, P14921, P43657, P62873, P63218, P50151, Q14344, Q7LDG7, P78417, O75293, P0DP23, P01568, P14784, P40189 | LAMB3, PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, PRKCA, MSH2, SMAD3, SMAD4, HDAC1, RARB, JUP, CCND3, BIRC3, VEGFC, ETS1, P2RY5, GNB1, GNG5, GNG10, GNA13, RASGRP2, GSTO1, GADD45B, CALM1, IFNA21, IL2RB, IL6ST | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13751 | LAMB3 | Laminin subunit beta-3 | -0.705 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.743 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.802 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.841 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.785 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P17252 | PRKCA | Protein kinase C alpha type | -0.725 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.925 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P10826 | RARB | Retinoic acid receptor beta | 0.779 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14923 | JUP | Junction plakoglobin | -0.716 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.747 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.871 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14921 | ETS1 | Protein C-ets-1 | 0.731 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.837 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.712 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.703 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.919 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P0DP23 | CALM1 | Calmodulin-1 | 0.926 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P01568 | IFNA21 | Interferon alpha-21 | -0.868 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.865 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.748 |
| | Frovatriptan | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | | Frovatriptan | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Frovatriptan | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | | Frovatriptan | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | | Frovatriptan | hsa05214 | Glioma | 2.73E-03 | 5 | P0DP23, P17252, P42338, P19174, O75293 | CALM1, PRKCA, PIK3CB, PLCG1, GADD45B | More | | | Frovatriptan | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | | Frovatriptan | hsa05222 | Small cell lung cancer | 1.10E-02 | 6 | P10826, P42338, Q13751, Q13489, P25963, O75293 | RARB, PIK3CB, LAMB3, BIRC3, NFKBIA, GADD45B | More | | | Frovatriptan | hsa05223 | Non-small cell lung cancer | 4.91E-03 | 5 | P17252, P42338, P19174, P10826, O75293 | PRKCA, PIK3CB, PLCG1, RARB, GADD45B | More | | | Frovatriptan | hsa05231 | Choline metabolism in cancer | 4.23E-04 | 6 | P42338, Q9Y259, P19174, P23743, P49619, P17252 | PIK3CB, CHKB, PLCG1, DGKA, DGKG, PRKCA | More | | | Frovatriptan | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.27E-02 | 4 | P19174, P07766, P06239, P01730 | PLCG1, CD3E, LCK, CD4 | More | | | Frovatriptan | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | | Frovatriptan | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Frovatriptan | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Frovatriptan | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | | Frovatriptan | hsa05340 | Primary immunodeficiency | 2.85E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | | Frovatriptan | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
|
